DPP-4 Therapy Center

The CAROLINA and CARMELINA Trials offer further information regarding the CV safety of linagliptin and glimepiride among patients with T2DM, high CVD risk, and decreased renal function.  

More may be better unless it involves tablets. A newly approved, more straightforward way to treat type 2 diabetes.

The persistence of benefits of dapagliflozin over saxagliptin might change therapy choices in patients with type 2 diabetes.

Diabetes has never been simpler to control with this once daily pill.

Study examines SGLT-2 inhibitors versus DPP-4 in reducing cardiovascular events.

A recent study demonstrates the efficacy of a new, once daily oral option for patients with type 2 diabetes already on metformin. 

A recent study reveals Liraglutide and Sitagliptin reduce intrahepatic lipid in patients with T2DM and IHL.

The CARMELINA trial demonstrated noninferiority of linagliptin compared with placebo in CV events in high risk people with type 2 diabetes. 

Sitagliptin showed greater glycemic efficacy over dapagliflozin when added onto existing therapy.

Prolonged use of medication increases risk of bowel condition, but exact cause yet to be determined.